Search

Your search keyword '"Wictor Aronsson-Kurttila"' showing total 3 results
Start Over Author "Wictor Aronsson-Kurttila"
3 results on '"Wictor Aronsson-Kurttila"'

1. Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis

Author

Arjang Baygan, Wictor Aronsson-Kurttila, Gianluca Moretti, Babylonia Tibert, Göran Dahllöf, Lena Klingspor, Britt Gustafsson, Bita Khoein, Guido Moll, Charlotta Hausmann, Britt-Marie Svahn, Magnus Westgren, Mats Remberger, Behnam Sadeghi, and Olle Ringden

Subjects
graft-versus-host disease, mesenchymal stromal cells, hematopoietic stem cell transplantation, hemorrhagic cystitis, decidual stromal cells, Immunologic diseases. Allergy, RC581-607
Abstract

Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 106 DSCs/kg. The patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months after the last DSC infusion. Three patients had transient reactions during DSC infusion. Laboratory values, hemorrhages, and transfusions were similar in the two groups. The frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were the same in the two groups. Causes of death were those seen in HSCT patients: infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC patients with GVHD was 67%, which was significantly better than achieved previously at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions appear safe. Randomized studies are required to prove efficacy.

Published
2017
Full Text
View/download PDF

2. Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation

Author

Arjang Baygan, Wictor Aronsson-Kurttila, Olle Ringdén, Mats Remberger, Gianluca Moretti, Bita Khoein, Behnam Sadeghi, and Guido Moll

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Placenta, Karyotype, Graft vs Host Disease, Pilot Projects, Hematopoietic stem cell transplantation, Gastroenterology, 03 medical and health sciences, Young Adult, Pregnancy, Internal medicine, Cause of Death, Cystitis, medicine, Decidua, Humans, Transplantation, Homologous, Adverse effect, Child, Fetus, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, General Medicine, Middle Aged, medicine.disease, Transplantation, 030104 developmental biology, Toxicity, Female, Stem cell, Neoplasm Grading, Stromal Cells, Complication, business, Hemorrhagic cystitis
Abstract

Background/Aims: Hemorrhagic cystitis (HC) is a serious complication after hematopoietic stem cell transplantation (HSCT). Stromal cells have been tested as therapy for HC. Decidua stromal cells (DSCs) protect the fetus from the mother's immune system. Methods: Eleven patients with HC of grades 3-4 were treated with DSCs after HSCT. The median age was 33 years (range 8-50), and the median dose of DSCs was 1.5 × 106/kg (range 0.7-2.5). The patients were given 1 dose (1-4). Results: In 5 patients, HC disappeared within 5 days after DSC infusion. Patients who received DSCs within 3 days after the start of HC had a duration of HC of 5 days and a shorter duration of pain than patients who were given DSCs later (p = 0.02). Three patients received DSCs prepared in albumin instead of AB-plasma and tended to have a shorter duration of pain (p = 0.07). There was no infusion toxicity. Adverse events were those often seen after HSCT. Nine of the 11 patients (82%) were alive 1 year after HSCT. Conclusions: Based on this pilot study, we started a randomized, placebo-controlled double-blind study using 2 doses of 1 × 106 DSCs/kg suspended in albumin for treatment of early HC.

Published
2017

3. Placenta-Derived Decidual Stromal Cells for Graft-Versus-Host Disease, Hemorrhaging, and Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation

Author

Pia Molldén, Martin Solders, Wictor Aronsson-Kurttila, Jonas Mattsson, Mats Remberger, Behnam Sadeghi, Magnus Westgren, Bita Khoein, Silvia Nava, Arjang Baygan, Helen Kaipe, Tom Erkers, Olle Ringdén, and Salimullah Mohmand

Subjects
Transplantation, Stromal cell, business.industry, medicine.medical_treatment, Hematology, Hematopoietic stem cell transplantation, medicine.disease, Graft-versus-host disease, medicine.anatomical_structure, Placenta, Toxicity, medicine, Cancer research, business
Published
2015

Catalog

Books, media, physical & digital resources
See catalog results